Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 406

1.

Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.

Eaton BR, Kim HS, Schreibmann E, Schuster DM, Galt JR, Barron B, Kim S, Liu Y, Landry J, Fox T.

J Vasc Interv Radiol. 2014 Feb;25(2):288-95. doi: 10.1016/j.jvir.2013.08.021. Epub 2013 Oct 23.

PMID:
24269792
2.

A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.

Kokabi N, Galt JR, Xing M, Camacho JC, Barron BJ, Schuster DM, Kim HS.

J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007.

PMID:
24461133
3.

Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.

Piduru SM, Schuster DM, Barron BJ, Dhanasekaran R, Lawson DH, Kim HS.

J Vasc Interv Radiol. 2012 Jul;23(7):943-8. doi: 10.1016/j.jvir.2012.04.010. Epub 2012 May 19.

PMID:
22609292
4.

Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.

Padia SA, Alessio A, Kwan SW, Lewis DH, Vaidya S, Minoshima S.

J Vasc Interv Radiol. 2013 Aug;24(8):1147-53. doi: 10.1016/j.jvir.2013.04.018. Epub 2013 Jun 20.

PMID:
23792126
5.

Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.

Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, Hendlisz A.

Phys Med Biol. 2008 Nov 21;53(22):6591-603. doi: 10.1088/0031-9155/53/22/019. Epub 2008 Oct 31. Erratum in: Phys Med Biol. 2014 May 21;59(10):2549-51. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.

PMID:
18978442
6.

Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.

Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM, Lewandowski RJ, Nagle C, Salem R.

J Vasc Interv Radiol. 2005 Aug;16(8):1101-6.

PMID:
16105922
7.

Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.

Lea WB, Tapp KN, Tann M, Hutchins GD, Fletcher JW, Johnson MS.

J Vasc Interv Radiol. 2014 Oct;25(10):1595-603. doi: 10.1016/j.jvir.2014.06.028. Epub 2014 Aug 23.

PMID:
25156647
8.

Intraprocedural yttrium-90 positron emission tomography/CT for treatment optimization of yttrium-90 radioembolization.

Bourgeois AC, Chang TT, Bradley YC, Acuff SN, Pasciak AS.

J Vasc Interv Radiol. 2014 Feb;25(2):271-5. doi: 10.1016/j.jvir.2013.11.004.

PMID:
24461132
9.

Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.

Burgmans MC, Kao YH, Irani FG, Dames EL, Teo TK, Goh AS, Chow PK, Tay KH, Lo RH.

J Vasc Interv Radiol. 2012 Oct;23(10):1294-301. doi: 10.1016/j.jvir.2012.07.009. Epub 2012 Aug 24.

PMID:
22922039
10.

PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation With Treatment Efficacy.

Song YS, Paeng JC, Kim HC, Chung JW, Cheon GJ, Chung JK, Lee DS, Kang KW.

Medicine (Baltimore). 2015 Jun;94(23):e945. doi: 10.1097/MD.0000000000000945.

11.

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M.

J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13.

12.

Outpatient single-session yttrium-90 glass microsphere radioembolization.

Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R.

J Vasc Interv Radiol. 2014 Feb;25(2):266-70. doi: 10.1016/j.jvir.2013.11.005. Epub 2013 Dec 12.

PMID:
24332243
13.

Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.

Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, Tay KH, Tan BS, Hoe Chow PK, Eng Ng DC, Whatt Goh AS.

J Nucl Med. 2012 Apr;53(4):559-66. doi: 10.2967/jnumed.111.097469. Epub 2012 Feb 17.

14.

Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.

Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozgur O, Bozcuk H, Sindel HT, Boz A.

Nucl Med Commun. 2015 Apr;36(4):340-9. doi: 10.1097/MNM.0000000000000257.

PMID:
25563137
15.

Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.

Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2015 Nov;56(11):1654-60. doi: 10.2967/jnumed.115.162685. Epub 2015 Aug 27.

PMID:
26315830
16.

Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography.

Campbell JM, Wong CO, Muzik O, Marples B, Joiner M, Burmeister J.

Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):313-20. doi: 10.1016/j.ijrobp.2008.12.058.

PMID:
19362251
17.

Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2013 Aug;54(8):1202-8. doi: 10.2967/jnumed.112.116426. Epub 2013 May 31.

18.

Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.

Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Porée P, Clément B, Raoul JL, Boucher E.

J Nucl Med. 2012 Feb;53(2):255-63. doi: 10.2967/jnumed.111.094235.

19.

Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.

Klingenstein A, Haug AR, Zech CJ, Schaller UC.

Cardiovasc Intervent Radiol. 2013 Feb;36(1):158-65. doi: 10.1007/s00270-012-0373-5. Epub 2012 Apr 21.

PMID:
22526099
20.

3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: feasibility study.

Fourkal E, Veltchev I, Lin M, Koren S, Meyer J, Doss M, Yu JQ.

Med Phys. 2013 Aug;40(8):081702. doi: 10.1118/1.4810939.

PMID:
23927299
Items per page

Supplemental Content

Write to the Help Desk